SAFETY DATA SHEET

Version 4.10 Revision Date 10/20/2016 Print Date 11/10/2018

1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifiers

Product name : (7-Azabenzotriazol-1-

yloxy)tripyrrolidinophosphonium

hexafluorophosphate

CAS-No. : 156311-83-0

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : Laboratory chemicals, Synthesis of substances

1.3 Details of the supplier of the safety data sheet

Company : Sigma-Aldrich

3050 Spruce Street SAINT LOUIS MO 63103

USA

Telephone : +1 800-325-5832 Fax : +1 800-325-5052

1.4 Emergency telephone number

Emergency Phone # : +1-703-527-3887 (CHEMTREC)

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)

Skin irritation (Category 2), H315 Eye irritation (Category 2A), H319

Specific target organ toxicity - single exposure (Category 3), Respiratory system, H335

For the full text of the H-Statements mentioned in this Section, see Section 16.

2.2 GHS Label elements, including precautionary statements

Pictogram

(!)

Signal word Warning

Hazard statement(s)

H315 Causes skin irritation.

H319 Causes serious eye irritation. H335 May cause respiratory irritation.

Precautionary statement(s)

P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.

P264 Wash skin thoroughly after handling.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves/ eye protection/ face protection.
P302 + P352 IF ON SKIN: Wash with plenty of soap and water.

P304 + P340 IF INHALED: Remove victim to fresh air and keep at rest in a position

comfortable for breathing.

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove

contact lenses, if present and easy to do. Continue rinsing.

P312 Call a POISON CENTER/doctor if you feel unwell.

P321 Specific treatment (see supplemental first aid instructions on this label).

P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P362 Take off contaminated clothing and wash before reuse.
P403 + P233 Store in a well-ventilated place. Keep container tightly closed.

P405 Store locked up.

P501 Dispose of contents/ container to an approved waste disposal plant.

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS - none

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Synonyms : PyAOP

(3-Hydroxy-3H-1,2,3-triazolo[4,5-b]pyridinato-O)tri-1-pyrrolidinyl-

phosphorous hexafluorophosphate

Formula : C₁₇H₂₇F₆N₇OP₂

Molecular weight : 521.38 g/mol

CAS-No. : 156311-83-0

Hazardous components

Component	Classification	Concentration
(7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate		
	Skin Irrit. 2; Eye Irrit. 2A;	<= 100 %
	STOT SE 3; H315, H319,	
	H335	

For the full text of the H-Statements mentioned in this Section, see Section 16.

4. FIRST AID MEASURES

4.1 Description of first aid measures

General advice

Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area. Hydrofluoric (HF) acid burns require immediate and specialized first aid and medical treatment. Symptoms may be delayed up to 24 hours depending on the concentration of HF. After decontamination with water, further damage can occur due to penetration/absorption of the fluoride ion. Treatment should be directed toward binding the fluoride ion as well as the effects of exposure. Skin exposures can be treated with a 2.5% calcium gluconate gel repeated until burning ceases. More serious skin exposures may require subcutaneous calcium gluconate except for digital areas unless the physician is experienced in this technique, due to the potential for tissue injury from increased pressure. Absorption can readily occur through the subungual areas and should be considered when undergoing decontamination. Prevention of absorption of the fluoride ion in cases of ingestion can be obtained by giving milk, chewable calcium carbonate tablets or Milk of Magnesia to conscious victims. Conditions such as hypocalcemia, hypomagnesemia and cardiac arrhythmias should be monitored for, since they can occur after exposure.

If inhaled

If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact

Wash off with soap and plenty of water. Consult a physician. First treatment with calcium gluconate paste.

In case of eye contact

Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11

4.3 Indication of any immediate medical attention and special treatment needed

No data available

5. FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

5.2 Special hazards arising from the substance or mixture

No data available

5.3 Advice for firefighters

Wear self-contained breathing apparatus for firefighting if necessary.

5.4 Further information

No data available

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. For personal protection see section 8.

6.2 Environmental precautions

Do not let product enter drains.

6.3 Methods and materials for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

6.4 Reference to other sections

For disposal see section 13.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Avoid contact with skin and eyes. Avoid formation of dust and aerosols.

Provide appropriate exhaust ventilation at places where dust is formed.

For precautions see section 2.2.

7.2 Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

Recommended storage temperature -20 °C

Keep in a dry place.

7.3 Specific end use(s)

Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components with workplace control parameters

Contains no substances with occupational exposure limit values.

8.2 Exposure controls

Appropriate engineering controls

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

Personal protective equipment

Eye/face protection

Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Body Protection

Impervious clothing, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Melting point/range: 163 - 168 °C (325 - 334 °F) - lit.

Respiratory protection

For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Control of environmental exposure

Do not let product enter drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Form: powder a) Appearance Colour: off-white

No data available Odour Threshold No data available

d) No data available

Melting point/freezing point

Initial boiling point and

boiling range

b) Odour

No data available

g) Flash point No data available No data available h) Evaporation rate i) Flammability (solid, gas) No data available

Upper/lower flammability or explosive limits No data available

k) Vapour pressure No data available Vapour density No data available m) Relative density No data available n) Water solubility No data available No data available Partition coefficient: n-

octanol/water

Auto-ignition temperature

No data available

Decomposition temperature

178 °C (352 °F) -

Viscosity No data available s) Explosive properties No data available

Oxidizing properties No data available

9.2 Other safety information

No data available

10. STABILITY AND REACTIVITY

10.1 Reactivity

No data available

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No data available

10.4 Conditions to avoid

No data available

10.5 Incompatible materials

Strong oxidizing agents

10.6 Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Carbon oxides, Nitrogen oxides (NOx), Oxides of phosphorus, Hydrogen fluoride

Other decomposition products - No data available

In the event of fire: see section 5

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity

No data available

Dermal: No data available

No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitisation

No data available

Germ cell mutagenicity

No data available

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as

probable, possible or confirmed human carcinogen by IARC.

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a

carcinogen or potential carcinogen by ACGIH.

NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a

known or anticipated carcinogen by NTP.

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a

carcinogen or potential carcinogen by OSHA.

Reproductive toxicity

No data available

No data available

Specific target organ toxicity - single exposure

Inhalation - May cause respiratory irritation.

Specific target organ toxicity - repeated exposure

No data available

Aspiration hazard

No data available

Additional Information

RTECS: Not available

Fluoride ion can reduce serum calcium levels possibly causing fatal hypocalcemia.

Salivation, Nausea, Vomiting, Fever, To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available as chemical safety assessment not required/not conducted

12.6 Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product

Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material.

Contaminated packaging

Dispose of as unused product.

14. TRANSPORT INFORMATION

DOT (US)

Not dangerous goods

IMDG

Not dangerous goods

IATA

Not dangerous goods

15. REGULATORY INFORMATION

SARA 302 Components

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards

Acute Health Hazard

Massachusetts Right To Know Components

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components

CAS-No.

Revision Date

(7-Azabenzotriazol-1-yloxy)tripyrrolidinophosphonium

hexafluorophosphate

156311-83-0

New Jersey Right To Know Components

CAS-No.

Revision Date

 $(7\hbox{-}Azabenzotriazol\hbox{-} 1\hbox{-} yloxy) tripyrrolidinophosphonium$

hexafluorophosphate

156311-83-0

California Prop. 65 Components

This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

16. OTHER INFORMATION

Full text of H-Statements referred to under sections 2 and 3.

Eye Irrit. Eye irritation

H315 Causes skin irritation.

H319 Causes serious eye irritation. H335 May cause respiratory irritation.

Skin Irrit. Skin irritation

STOT SE Specific target organ toxicity - single exposure

HMIS Rating

Health hazard: 2

Chronic Health Hazard:

Flammability: 0 Physical Hazard 0

NFPA Rating

Health hazard: 2
Fire Hazard: 0
Reactivity Hazard: 0

Further information

Copyright 2016 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

Preparation Information

Sigma-Aldrich Corporation Product Safety – Americas Region 1-800-521-8956

Version: 4.10 Revision Date: 10/20/2016 Print Date: 11/10/2018